Oncology Data Advisor - New Durvalumab Dose Approved: NSCLC, Urothelial Carcinoma
Astrazeneca Imfinzi (Durvalumab), Dosage Form: Injection, Single Use Vial at Rs 48000/vial in Patiala
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
IMFINZI® (durvalumab) Dosing for Advanced BTCs
Imfinzi Dosage Guide - Drugs.com
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet
Dosing & Administration - IMFINZI® (durvalumab)
IMFINZI Dosage & Rx Info | Uses, Side Effects
Durvalumab in NSCLC: latest evidence and clinical potential - Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares, 2018
AstraZeneca's Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option | EuropaWire.eu | The European Union's press release distribution & newswire service
Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug | MedPage Today
Easy Durvalumab Dosing - 2 MCQs | The Discreet Pharmacist
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma - ScienceDirect
Dosing & Administration - IMFINZI® (durvalumab)
IMFINZI® (durvalumab) & IMJUDO® (tremelimumab-actl) Dosing for Unresectable HCC
Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Tumor response to durvalumab in the study 1108, a dose escalation and... | Download Table
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study - The Lancet Oncology
Dosing & Administration - IMFINZI® (durvalumab)
A) Real-world PFS and (B) OS according to durvalumab dosing schedule.... | Download Scientific Diagram
DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment | BMC Cancer | Full Text
Imfinzi Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
Cancers | Free Full-Text | Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity
Durvalumab (Imfinzi) - Uses, Dose, Side effects, MOA, Brands
